A Phase 1 interventional study of DM-101PX and Placebo to Match DM-101PX in Birch Pollen Allergy, sponsored by Desentum Oy. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-25.
Sponsored by Desentum Oy · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada — 2 open to participants now, 3 under way, none of them phase 3. Rhinitis, Allergic, Seasonal · Canada.
Among the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada, this one is the 30th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2023, is one of 4 in phase 1, and was the 28th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →2 of the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada are open now. Recruiting first, the newest first:
Dr. Anne Ellis · Sites in Canada
Ages 18–70 · Healthy volunteers
Alixer Nexgen Therapeutics Limited · Sites in Canada
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 104 across the 32 interventional studies, 12 across the 1 observational. Of the 30 that completed or were terminated, 5 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 33 have an industry lead sponsor. The 10 most frequent:
Desentum Oy is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Desentum Oy has 4 studies filed under Rhinitis, Allergic, Seasonal — fewer than ten, so there is no comparison to draw.
1 of the studies in Rhinitis, Allergic, Seasonal with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06189742Dr. Anne EllisTezepelumab in Allergic Rhinitis and Asthma Study (TEZARS) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies in Rhinitis, Allergic, Seasonal with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of three ascending dosing schemes of DM-101-PX in birch pollen allergic adults. As an explorative objective, the trial will also investigate the effect of DM-101PX on the allergic symptoms following birch pollen allergen exposure in a chamber. Expanded access to the study treatment is not available.
The study will be carried out in a single study site located in Canada
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 subcutaneous doses starting from 0.05 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
Biological: DM-101PX
10 subcutaneous doses.First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
Biological: Placebo to Match DM-101PX
10 subcutaneous doses starting from 0.1 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
Biological: DM-101PX
10 subcutaneous doses starting from 0.2 ug of which first 8 doses are ascending. Thereafter the 8th dose is repeated twice. First 9 doses are administered at 1 week interval, and the 10th dose is administered 2 weeks after the 9th dose.
Biological: DM-101PX
subcutaneous injection of DM-101PX
Placebo to match DM-101PX administered subcutaneously
Treatment Emergent Adverse Events
Occurrence of treatment emergent adverse events
Time frame: From the first dose to until 14-28 days from the last dose
Adverse Events of Special Interest
Occurrence of local injection site reactions and systemic allergic reactions
Time frame: From the first dose to until 14-28 days from the last dose
Subjects Reaching the Maximum Intended Dose
Number of subjects in each cohort who reach the maximum intended dose
Time frame: Through the treatment period, an average of 10 weeks
Plan to share: Yes — All individual participant data that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to patient level data and related study documents: patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants after Desentum has received marketing authorization from major health authorities (e.g. FDA, EMA), has the legal authority to share the data, and has made the study results publicly available.
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Mar 2024, 5 months.
Of 16 phase 1 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 9. This study's 5 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DM-101PX
Rhinitis, Allergic, Seasonal →
Desentum Oy